Epigenetic Reprogramming Gene Therapy Shows Early Vision Gains in First Human Glaucoma Trial
Life Bio's ER-100, which delivers OSK reprogramming factors to the eye, was well tolerated in three glaucoma patients, and two showed visual field gains.
Summary
Life Biosciences has released interim data from the first human trial of partial epigenetic reprogramming. The therapy, ER-100, is a single injection into the eye that delivers three reprogramming genes (OCT4, SOX2 and KLF4, known as OSK). Daily doxycycline pills switch the genes on for 56 days. Three people with open-angle glaucoma, a leading cause of blindness in older adults, received the lowest dose. The treatment was well tolerated, with no dose-limiting toxicities or serious adverse events. Two of the three participants showed improved visual field scores at Day 56. Safety reviewers cleared the trial to move to a higher dose. The trial is a small, open-label Phase 1 safety study, so the vision signals are preliminary and could reflect chance or other factors. Still, it is the first human test of an idea long studied in animals: resetting the age-related epigenetic changes that damage cells, potentially restoring function that was thought to be permanently lost.
Detailed Summary
Why this matters: Glaucoma is a chronic neurodegenerative disease and a leading cause of blindness in older adults. Retinal ganglion cells, the neurons that link the eye to the brain, do not regenerate, so lost vision is usually considered permanent. Current treatments mainly lower eye pressure, yet the disease often keeps progressing, and some patients develop it despite normal pressure. A therapy that restored damaged neurons would be a major shift.
Main findings: Life Biosciences reported interim results from its first-in-human Phase 1 trial (NCT07290244) of ER-100. The therapy uses a single intravitreal injection of an AAV-2 vector carrying three transcription factors, OSK (OCT4, SOX2, KLF4). Daily oral doxycycline for 56 days turns on their expression, and a prednisolone taper limits inflammation from the viral vector. Three people with open-angle glaucoma received the first dose level (2×10^11 vg). All tolerated it through Day 56, with no dose-limiting toxicities, serious adverse events or adverse events of special interest. Reported adverse events were tied to the procedure, steroid use or pre-existing conditions. Two of the three showed visual field improvement on Humphrey testing, with at least 28% of tested points gaining more than 4 dB.
Key insights: The Data Safety Monitoring Board recommended escalating to Dose Level 2 (6×10^11 vg). The dosing switch lets researchers control when OSK is active, an important safeguard because uncontrolled reprogramming can cause cells to lose identity or form tumors. The trial also covers other optic neuropathies, including NAION, which has no approved treatment.
Practical implications: Nothing here is available to patients outside a trial. It does show that partial epigenetic reprogramming can be tested safely in humans, at least at this dose and timeframe. Readers with glaucoma should keep following standard care and discuss trial eligibility with an ophthalmologist.
Caveats: The data come from a company press release covering three participants in an open-label study with no control group. Day 56 is a short follow-up. Visual field tests vary from visit to visit, so improvements may reflect testing variability. Longer follow-up, larger numbers and peer-reviewed data are needed to confirm both safety and benefit.
Key Findings
- ER-100 plus doxycycline was well tolerated in three open-angle glaucoma patients through Day 56, with no serious or dose-limiting adverse events.
- Two of three participants showed visual field gains, with at least 28% of tested points improving by more than 4 dB.
- The safety board recommended escalating to a three-fold higher dose (6×10^11 vg) as the trial continues.
- Doxycycline-controlled OSK expression lets researchers switch the reprogramming genes on for a defined 8-week window.
- This is the first human test of partial epigenetic reprogramming, not yet proof of efficacy.
Methodology
This is a news report of a company press release on interim Phase 1 data, republished by Lifespan.io. The trial is registered (NCT07290244), but the results are not peer reviewed. The evidence base is three participants in an open-label study with 56 days of follow-up.
Study Limitations
With only three participants, no control group and a short follow-up, the visual field improvements cannot be separated from test variability or placebo-type effects. The article is sponsor-reported and lacks full methods, individual patient data and long-term safety results. Verify against the trial registry and any future peer-reviewed publication.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: